Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Cipla
Dow
Federal Trade Commission
Harvard Business School
US Army
Cantor Fitzgerald
US Department of Justice
Healthtrust
Daiichi Sankyo

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,020,358

« Back to Dashboard

Which drugs does patent 6,020,358 protect, and when does it expire?

Patent 6,020,358 protects OTEZLA and is included in one NDA.

This patent has twenty-six patent family members in fifteen countries.
Summary for Patent: 6,020,358
Title: Substituted phenethylsulfones and method of reducing TNF.alpha. levels
Abstract:Phenethylsulfones substituted in the position .alpha. to the phenyl group with a 1-oxoisoindoline or 1,3-dioxoisoindoline group reduce the levels of TNF.alpha. in a mammal. Typical embodiments are 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-aminoisoindoline- 1,3-dione and 2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-2-methylsulfonylethyl]isoindoline- 1,3-dione.
Inventor(s): Muller; George W. (Bridgewater, NJ), Man; Hon-Wah (Neshanic Station, NJ)
Assignee: Celgene Corporation (Warren, NJ)
Application Number:09/183,049
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent 6,020,358

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Celgene Corp OTEZLA apremilast TABLET;ORAL 205437-001 Mar 21, 2014 RX Yes No ➤ Sign Up ➤ Sign Up Y Y USE OF OTEZLA (APREMILAST) FOR INHIBITING PDE4 ➤ Sign Up
Celgene Corp OTEZLA apremilast TABLET;ORAL 205437-002 Mar 21, 2014 RX Yes No ➤ Sign Up ➤ Sign Up Y Y USE OF OTEZLA (APREMILAST) FOR INHIBITING PDE4 ➤ Sign Up
Celgene Corp OTEZLA apremilast TABLET;ORAL 205437-003 Mar 21, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y USE OF OTEZLA (APREMILAST) FOR INHIBITING PDE4 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,020,358

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,011,050 Substituted phenethylsulfones and method of reducing TNF.alpha. levels ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,020,358

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Norway 319790 ➤ Sign Up
Norway 20012021 ➤ Sign Up
Japan 4530543 ➤ Sign Up
Japan 2002528496 ➤ Sign Up
Hong Kong 1103224 ➤ Sign Up
Hong Kong 1038696 ➤ Sign Up
Spain 2421153 ➤ Sign Up
Spain 2343744 ➤ Sign Up
Spain 2278467 ➤ Sign Up
European Patent Office 2305248 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Queensland Health
US Army
Deloitte
McKinsey
AstraZeneca
US Department of Justice
UBS
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot